Rapid Medicals TIGERTRIEVER Delivers First-Pass Success in Challenging Ischemic Stroke Patients with ICAD
| ICAD Stock | USD 2.13 0.16 8.12% |
About 56% of all Icad's shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding icad inc suggests that some traders are interested. The current market sentiment, together with Icad's historical and current headlines, can help investors time the market. In addition, many technical investors use icad inc stock news signals to limit their universe of possible portfolio assets.
Icad |
Rapid Medical, a leading developer of advanced neurovascular devices, announces new data demonstrating excellent first-pass treatment success with th
Read at businesswire.com
 |
Icad Fundamental Analysis
We analyze Icad's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Icad using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Icad based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Icad is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
icad inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Icad stock to make a market-neutral strategy. Peer analysis of Icad could also be used in its relative valuation, which is a method of valuing Icad by comparing valuation metrics with similar companies.
Peers
Icad Related Equities
| AXGN | Axogen | 4.86 | ||||
| FNA | Paragon 28 | 4.32 | ||||
| SIBN | Si Bone | 3.59 | ||||
| NVNO | EnVVeno Medical | 3.46 | ||||
| ESTA | Establishment Labs | 2.89 | ||||
| NVRO | Nevro Corp | 2.41 | ||||
| CVRX | CVRx | 1.85 | ||||
| SRDX | SurModics | 0.66 | ||||
| SGHT | Sight Sciences | 0.35 | ||||
| MOVE | Movano | 0.36 | ||||
| PROF | Profound Medical | 0.41 | ||||
| SSKN | STRATA Skin | 1.03 | ||||
| AIMD | Ainos | 1.59 | ||||
| LNSR | LENSAR | 1.80 | ||||
| BMRA | Biomerica | 9.86 |
Complementary Tools for Icad Stock analysis
When running Icad's price analysis, check to measure Icad's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Icad is operating at the current time. Most of Icad's value examination focuses on studying past and present price action to predict the probability of Icad's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Icad's price. Additionally, you may evaluate how the addition of Icad to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |